Microneedle Device For Transport Of Molecules Across Tissue by Prausnitz, Mark R. et al.
(12) United States Patent 
Prausnitz et al. 
(54) MICRONEEDLE DEVICE FOR TRANSPORT 
OF MOLECULES ACROSS TISSUE 
(75) Inventors: Mark R. Prausnitz, Atlanta, GA (US); 
Mark G. Allen, Atlanta, GA (US); 
Devin V. McAllister, Holley, NY (US); 
Sebastien Henry, Ay (FR) 
(73) Assignee: Georgia Tech Research Corporation, 
Atlanta, GA (US) 
( *) Notice: This patent issued on a continued pros-
ecution application filed under 37 CFR 
1.53( d), and is subject to the twenty year 
patent term provisions of 35 U.S.C. 
154(a)(2). 
Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 0 days. 









Filed: Jun. 10, 1998 
Int. Cl.7 ................................................. A61M 5/32 
U.S. Cl. ........................................ 604/272; 604/191 
Field of Search .............................. 935/53; 604/20, 
604/22, 35, 46, 501, 506, 181, 183, 239, 
261, 890.1, 272, 191, 186; 347/47; 29/890.01; 
424/449, 483; 216/75, 100, 102 
References Cited 
U.S. PATENT DOCUMENTS 
2,893,392 A 
3,034,507 A 
7/1959 Wagner et al. 
5/1962 McConnell et al. 
(List continued on next page.) 







I lllll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111 
US006503231Bl 
(10) Patent No.: US 6,503,231 Bl 



































"101 Uses for Tiny Tubules," Science247 (1990). 
Zuska, "Microtechnology Opens Doors to the Universe of 
Small Space," Medical Device and Diagnostic Industry,p. 
131 (Jan. 1997). 
"Single-crystal whiskers," Biophotonics Int'l, p. 64 (Nov./ 
Dec. 1996). 
Edell, et al., "Factors Influencing the Biocompatibility of 
Insertable Silicon Microshafts in Cerebral Cortex," IEEE 
Transactions on Biomedical Engineering39(6):635-43 
(1992). 
(List continued on next page.) 
Primary Examiner---Anhtuan T. Nguyen 
(74) Attorney, Agent, or Firm-Ropes & Gray 
(57) ABSTRACT 
Microneedle devices for transport of therapeutic and diag-
nostic materials and/or energy across tissue barriers, and 
methods for manufacturing the devices, are provided. The 
microneedles are hollow and/or porous and have diameters 
between about 10 nm and 1 mm. The microneedle devices 
permit drug delivery (or removal or sensing of body fluids) 
at clinically relevant rates across skin or other tissue barriers, 
without damage, pain, or irritation to the tissue. Microfab-
rication techniques are used to cost-effectively produce 
arrays of microneedles from metals, silicon, silicon dioxide, 
ceramic, and polymeric materials. Methods are provided for 
making porous or hollow microneedles. 
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MICRONEEDLE DEVICE FOR TRANSPORT 
OF MOLECULES ACROSS TISSUE 
2 
over a period of hours or days. Attempts have been made to 
design alternative devices for active transfer of drugs, or 
analyte to be measured, through the skin. 
For example, WO 96/37256 by Silicon Microdevices, Inc. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
Not applicable. 
BACKGROUND OF THE INVENTION 
5 (Godshall) discloses a transdermal drug delivery apparatus 
that includes a cutter portion having a plurality of 
microprotrusions, which have straight sidewalls, extending 
from a substrate that is in communication with a drug 
reservoir. In operation, the microprotrusions penetrate the 
This invention is generally in the field of devices for the 
transport of therapeutic or biological molecules across tissue 
barriers, such as for drug delivery. 
Numerous drugs and therapeutic agents have been devel-
oped in the battle against disease and illness. However, a 
frequent limitation of these drugs is their delivery: how to 
transport drugs across biological barriers in the body (e.g., 
the skin, the oral mucosa, the blood-brain barrier), which 
normally do not transport drugs at rates that are therapeu-
tically useful. 
10 skin until limited by a stop region of the substrate and then 
are moved parallel to the skin to create incisions. Because 
the microprotrusions are dragged across the skin, the device 
creates a wound sufficiently large to be a site of infection. 
Channels in the substrate adjacent to the microprotrusions 
15 allow drug from the reservoir to flow to the skin near the area 
disrupted by the microprotrusions. 
Drugs are commonly administered orally as pills or 
capsules. However, many drugs cannot be effectively deliv-
ered in this manner, due to degradation in the gastrointestinal 
tract and/or elimination by the liver. Moreover, some drugs 
cannot effectively diffuse across the intestinal mucosa. 
Patient compliance may also be a problem, for example, in 
therapies requiring that pills be taken at particular intervals 
over a prolonged time. 
U.S. Pat. No. 5,250,023 to Lee et al. discloses a trans-
dermal drug delivery device, which includes a plurality of 
skin needles having a diameter in the range of 50 to 400 µm. 
20 The skin needles are supported in a water-swellable polymer 
substrate through which a drug solution permeates to contact 
the surface of the skin. An electric current is applied to the 
device to open the pathways created by the skin needles, 
following their withdrawal from the skin upon swelling of 
25 the polymer substrate. 
WO 93/17754 by Gross et al. discloses another transder-
mal drug delivery device that includes a housing having a 
liquid drug reservoir and a plurality of tubular elements for 
30 
transporting liquid drug into the skin. The tubular elements 
may be in the form of hollow needles having inner diameters 
of less than 1 mm and an outer diameter of 1.0 mm. 
Another common technique for delivering drugs across a 
biological barrier is the use of a needle, such as those used 
with standard syringes or catheters, to transport drugs across 
(through) the skin. While effective for this purpose, needles 
generally cause pain; local damage to the skin at the site of 
insertion; bleeding, which increases the risk of disease 35 
transmission; and a wound sufficiently large to be a site of 
infection. The withdrawal of bodily fluids, such as for 
diagnostic purposes, using a conventional needle has these 
same disadvantages. Needle techniques also generally 
require administration by one trained in its use. The needle 40 
technique also is undesirable for long term, controlled 
continuous drug delivery. 
Similarly, current methods of sampling biological fluids 
are invasive and suffer from the same disadvantages. For 
example, needles are not preferred for frequent routine use, 45 
such as sampling of a diabetic's blood glucose or delivery of 
insulin, due to the vascular damage caused by repeated 
punctures. No alternative methodologies are currently in 
use. Proposed alternatives to the needle require the use of 
lasers or heat to create a hole in the skin, which is 50 
inconvenient, expensive, or undesirable for repeated use. 
An alternative delivery technique is the transdermal 
patch, which usually relies on diffusion of the drug across 
the skin. However, this method is not useful for many drugs, 
due to the poor permeability (i.e. effective barrier properties) 55 
of the skin. The rate of diffusion depends in part on the size 
and hydrophilicity of the drug molecules and the concen-
tration gradient across the stratum corneum. Few drugs have 
the necessary physiochemical properties to be effectively 
delivered through the skin by passive diffusion. 60 
Iontophoresis, electroporation, ultrasound, and heat (so-
called active systems) have been used in an attempt to 
improve the rate of delivery. While providing varying 
degrees of enhancement, these techniques are not suitable 
for all types of drugs, failing to provide the desired level of 65 
delivery. In some cases, they are also painful and inconve-
nient or impractical for continuous controlled drug delivery 
While each of these devices has potential use, there 
remains a need for better drug delivery devices, which make 
smaller incisions, deliver drug with greater efficiency 
(greater drug delivery per quantity applied) and less vari-
ability of drug administration, and/or are easier to use. 
It is therefore an object of the present invention to provide 
a microneedle device for relatively painless, controlled, safe, 
convenient transdermal delivery of a variety of drugs. 
It is another object of the present invention to provide a 
microneedle device for controlled sampling of biological 
fluids in a minimally-invasive, painless, and convenient 
manner. 
SUMMARY OF THE INVENTION 
Microneedle devices for transport of therapeutic and 
biological molecules across tissue barriers, and methods for 
manufacturing the devices, are provided. The microneedles 
have diameters between about 10 nm and 1 mm, and 
preferably are hollow or porous. The microneedle devices 
permit drug delivery or removal of body fluids at clinically 
relevant rates across skin or other tissue barriers, with 
minimal or no damage, pain, or irritation to the tissue. 
Microfabrication techniques are used to cost-effectively 
produce arrays of microneedles from metals, silicon, and 
polymeric materials. Methods are provided for making 
porous or hollow microneedles. 
For transdermal drug delivery applications, the depth of 
penetration of the microneedles preferably is in the range of 
between about 10 µIm and 100 µm, so as to penetrate the 
stratum corneum barrier without penetrating into the dermis, 
thereby avoiding pain or bleeding, and the diameter of 
transport pathways created in the skin are preferably less 
than about 1 µm, to avoid making a hole which would allow 
bacteria to enter the penetration wound. The microneedles 
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are also useful for minimally invasive diagnosis of biologi-
cal fluids. A preferred embodiment of such biosensors is for 
use in monitoring blood glucose levels, as well as delivery 
of therapeutics such as insulin. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a cross-sectional view of human skin. 
FIG. 2 is a side elevational view of a preferred embodi-
ment of the microneedle device. 
FIG. 3 is a cross-sectional view of a preferred embodi-
ment of the microneedle device applied to human skin. 
FIG. 4 is a diagram of one embodiment of microneedles. 
4 
b. Microneedle 
The microneedles of the device can be constructed from 
a variety of materials, including metals, ceramics, 
semiconductors, organics, polymers, and composites. The 
5 microneedles must have the mechanical strength to remain 
intact and to deliver drugs, or collect biological fluid, while 
being inserted into the skin, while remaining in place for up 
to a number of days, and while being removed. The micron-
eedles should be sterilizable using standard methods. 
10 
FIGS. Sa and Sb are top and side cross-sectional views, 
respectively, of a preferred embodiment of a hollow micron- 15 
eedle. 
The microneedles can be porous or hollow. As used 
herein, the term "porous" means having pores or voids 
throughout at least a portion of the microneedle structure, 
sufficiently large and sufficiently interconnected to permit 
passage of fluid and/or solid materials through the micron-
eedle. As used herein, the term "hollow" means having one 
or more substantially annular bores or channels through the 
FIGS. 6a through 6d are side cross-sectional views illus-
trating a preferred method for making hollow microneedles. 
DETAILED DESCRIPTION OF THE 
INVENTION 
1. Biological Barriers 
interior of the microneedle structure, having a diameter 
sufficiently large to permit passage of fluid and/or solid 
materials through the microneedle. A solid or porous 
20 microneedle can be hollow. One of skill in the art can select 
The devices disclosed herein are useful in transport of 
material into or across biological barriers including the skin 
(or parts thereof); the blood-brain barrier; mucosal tissue 25 
(e.g., oral, nasal, ocular, vaginal, urethral, gastrointestinal, 
respiratory); blood vessels; lymphatic vessels; or cell mem-
branes (e.g., for the introduction of material into the interior 
the appropropriate porosity and/or bore features required for 
specific applications. For example, one can adjust the pore 
size or bore diameter to permit passage of the particular 
material to be transported through the microneedle device. 
c. Reservoir 
The microneedle device may include a reservoir in com-
munication with the microneedles. In a preferred 
embodiment, the reservoir contains drug, for delivery 
through the microneedles. The reservoir may be a hollow of a cell or cells). The biological barriers could be in humans 
or other types of animals, as well as in plants, insects, or 
other organisms, including bacteria, yeast, fungi, and 
embryos. 
For internal tissues, application of the microneedle 
devices can be achieved with the aid of a catheter or 
laparoscope. For certain applications, such as for drug 
delivery to an internal tissue, the devices can be surgically 
implanted. 
Skin is a biological barrier of particular use with the 
microneedle device disclosed herein. A schematic of human 
skin is shown in FIG. 1. The stratum corneum is the outer 
layer, generally between 10 and 50 cells, or between 10 and 
20 µIm thick. Unlike other tissue in the body, the stratum 
corneum contains "cells" (called keratinocytes) filled with 
bundles of cross-linked keratin and keratohyalin surrounded 
by an extracellular matrix of lipids. It is this structure that is 
believed to give skin its barrier properties, which prevents 
therapeutic transdermal administration of many drugs. 
Below the stratum corneum is the viable epidermis, which 
30 vessel, a porous matrix, or a solid form including drug which 
is transported therefrom. The reservoir can be formed from 
a variety of materials that are compatible with the drug or 
biological fluid contained therein. Preferred materials 
include natural and synthetic polymers, metals, ceramics, 
35 semiconductors, organics, and composites. 
In a preferred embodiment, the reservoir should be in 
direct contact with the microneedles and have holes through 
which drug could exit the reservoir and flow into the interior 
of hollow or porous microneedles. In another preferred 
40 embodiment, the reservoir has holes which permit the drug 
to transport out of the reservoir and onto the skin surface. 
From there, drug is transported into the skin, either through 
hollow or porous microneedles, along the sides of solid 
microneedles, or through pathways created by microneedles 
45 in the skin. 
d. Transport Control Components 
The microneedle device also must be capable of trans-
is between 50 and 100 µm thick. The viable epidermis 
contains no blood vessels, and it exchanges metabolites by 50 
diffusion to and from the dermis. 
porting material across the barrier at a useful rate. For 
example, the microneedle device must be capable of deliv-
ering drug across the skin at a rate sufficient to be thera-
peutically useful. The device may include a housing with 
Beneath the viable epidermis is the dermis, which is 
between 1 and 3 mm thick and contains blood vessels, 
lymphatics, and nerves. 
2. The Microneedle Device 
The microneedle devices disclosed herein include a sub-
strate; one or more microneedles; and, optionally, a reservoir 
for delivery of drugs or collection of analyte, a pump(s), 
sensor(s), and microprocessor(s) to control the interaction of 
the foregoing. 
a. Substrate 
The substrate of the device can be constructed from a 
variety of materials, including metals, ceramics, 
semiconductors, organics, polymers, and composites. The 
substrate includes the base to which the microneedles are 
attached or integrally formed. A reservoir may also be 
attached to the substrate. 
microelectronics and other micromachined structures to 
control the rate of delivery either according to a prepro-
grammed schedule or through active interface with the 
55 patient, a healthcare professional, or a biosensor. The rate 
can be controlled by manipulating a variety of factors, 
including the characteristics of the drug formulation to be 
delivered (e.g., its viscosity, electric charge, and chemical 
composition); the dimensions of each microneedle (e.g., its 
60 outer diameter and the area of porous or hollow openings); 
the number of micro needles in the device; the application of 
a driving force (e.g., a concentration gradient, a voltage 
gradient, a pressure gradient); and the use of a valve. 
The rate also can be controlled by interposing between the 
65 drug in the reservoir and the opening(s) at the base end of the 
microneedle polymeric or other materials selected for their 
diffusion characteristics. For example, the material compo-
US 6,503,231 Bl 
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sition and layer thickness can be manipulated using methods 
known in the art to vary the rate of diffusion of the drug of 
interest through the material, thereby controlling the rate at 
which the drug flows from the reservoir through the micron-
eedle and into the tissue. 
Transportation of molecules through the micro needles can 
be controlled or monitored using, for example, various 
combinations of pumps, sensors, actuators, and micropro-
cessors. These components can be produced using standard 
manufacturing or microfabrication techniques. Actuators 
that may be useful with the microneedle devices disclosed 
herein include micropumps, microvalves, and positioners. In 
a preferred embodiment, a microprocessor is programmed to 
control a pump or valve, thereby controlling the rate of 
delivery. 
6 
The diameter of each microneedle 12 generally is between 
about 10 nm and 1 mm, and preferably leaves a residual hole 
(following microneedle insertion and withdrawal) of less 
than about 1 µm, to avoid making a hole which would allow 
5 bacteria to enter the penetration wound. The actual micron-
eedle diameter should be larger than 1 µm, since the hole 
likely will contract following withdrawal of the micron-
eedle. The diameter of microneedle 12 more preferably is 
between about 1 µm and 100 µm. In a preferred embodiment, 
10 
the diameter of the micro needle is greatest at the base end of 
the microneedle and tapers to a point at the end distal the 
base. Larger diameter and longer microneedles are 
acceptable, so long as the microneedle can penetrate the 
biological barrier to the desired depth and the hole remain-
ing in the skin or other tissue following withdrawal of the 
15 microneedle is sufficiently small, preferably small enough to 
exclude bacterial entry. The microneedles 12 can be solid or 
porous, and can include one or more bores connected to 
upper portion 11. 
Useful sensors may include sensors of pressure, 
temperature, chemicals, and/or electromagnetic fields. Bio-
sensors can be located on the microneedle surface, inside a 
hollow or porous microneedle, or inside a device in com-
munication with the body tissue via the microneedle (solid, 
hollow, or porous). These microneedle biosensors can 20 
include four classes of principal transducers: potentiometric, 
amperometric, optical, and physiochemical. An amperomet-
3. Methods of Making Microneedle Devices 
The microneedle devices are made by microfabrication 
processes, by creating small mechanical structures in silicon, 
metal, polymer, and other materials. These microfabrication 
processes are based on well-established methods used to 
make integrated circuits and other microelectronic devices, 
ric sensor monitors currents generated when electrons are 
exchanged between a biological system and an electrode. 
Blood glucose sensors frequently are of this type. 25 augmented by additional methods developed by workers in 
the field of micromachining. The microneedle devices can 
have dimensions as small as a few nanometers and can be 
mass-produced at low per-unit costs. 
The microneedle may function as a conduit for fluids, 
solutes, electric charge, light, or other materials. In one 
embodiment, hollow microneedles can be filled with a 
substance, such as a gel, that has a sensing functionality 
associated with it. In an application for sensing based on 
30 binding to a substrate or reaction mediated by an enzyme, 
the substrate or enzyme can be immobilized in the needle 
interior, which would be especially useful in a porous needle 
to create an integral needle/sensor. 
a. Microfabrication Processes 
Microfabrication processes that may be used in making 
the microneedles disclosed herein include lithography; etch-
ing techniques, such as wet chemical, dry, and photoresist 
removal; thermal oxidation of silicon; electroplating and 
electroless plating; diffusion processes, such as boron, Wave guides can be incorporated into the microneedle 
device to direct light to a specific location. Similarly, heat, 
electricity, or other energy forms may be precisely trans-
mitted to directly stimulate, damage, or heal a specific tissue 
or intermediary. 
FIG. 2 is a side elevational view of a schematic of a 
preferred embodiment of the microneedle device. FIG. 3 is 
a schematic diagram of the same microneedle device 
inserted into skin. The device 10 includes an upper portion 
35 phosphorus, arsenic, and antimony diffusion; ion implanta-
tion; film deposition, such as evaporation (filament, electron 
beam, flash, and shadowing and step coverage), sputtering, 
chemical vapor deposition (CVD), epitaxy (vapor phase, 
liquid phase, and molecular beam), electroplating, screen 
40 printing, and lamination. See generally Jaeger, Introduction 
to Microelectronic Fabrication (Addison-Wesley Publishing 
Co., Reading Mass. 1988); Runyan, et al., Semiconductor 
Integrated Circuit Processing Technology (Addison-Wesley 
Publishing Co., Reading Mass. 1990); Proceedings of the 
or substrate 11 from which a plurality of microneedles 12 
protrude. The height of the upper portion 11 is between 
about 1 µIm and 1 cm, and the width of the upper portion is 
between about 1 mm and 10 cm. The upper portion 11 of the 
device can be solid or hollow, and may include multiple 
compartments. In a preferred embodiment for drug delivery, 
the upper portion 11 contains one or more drugs to be 
delivered. It is also preferred that the upper portion include 50 
one or more sensors and/or an apparatus (e.g., pump or 
electrode) to drive (provide/direct the force) transport of the 
drug or other molecules. 
45 IEEE Micro Electro Mechanical Systems Conference 
1987-1998; Rai-Choudhury, ed., Handbook of Microlithog-
raphy. Micromachining & Micro/ abrication (SPIE Optical 
Engineering Press, Bellingham, Wash. 1997). The following 
methods are preferred for making microneedles. 
i. Electrochemical Etching of Silicon 
In this method, electrochemical etching of solid silicon to 
porous silicon is used to create extremely fine (on the order 
of 0.01 µm) silicon networks which can be used as piercing 
structures. This method uses electrolytic anodization of 
55 silicon in aqueous hydrofluoric acid, potentially in combi-
nation with light, to etch channels into the silicon. By 
varying the doping concentration of the silicon wafer to be 
etched, the electrolytic potential during etching, the incident 
light intensity, and the electrolyte concentration, control 
The height (or length) of the microneedles 12 generally is 
between about 1 µm and 1 cm. In transdermal applications, 
the "insertion depth" of the microneedles 12 is preferably 
less than about 100 µm, more preferably about 30 µIm, so 
that insertion of the microneedles 12 into the skin does not 
penetrate into the dermis (as described below), thereby 
avoiding contacting nerves which may cause pain. In such 
applications, the actual length of the microneedles may be 
longer, since the portion of the microneedles distal the tip 
may not be inserted into the skin; the uninserted length 
depends on the particular device design and configuration. 
The actual (overall) height or length of micro needles 12 65 
should be equal to the insertion depth plus the uninserted 
length. 
60 over the ultimate pore structure can be achieved. The 
material not etched (i.e. the silicon remaining) forms the 
microneedles. This method has been used to produce irregu-
lar needle-type structures measuring tens of nanometers in 
width. 
ii. Plasma Etching 
This process uses deep plasma etching of silicon to create 
microneedles with diameters on the order of 0.1 µm or 
US 6,503,231 Bl 
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larger. Needles are patterned directly using 
photolithography, rather than indirectly by controlling the 
voltage (as in electrochemical etching), thus providing 
greater control over the final microneedle geometry. 
In this process, an appropriate masking material (e.g., 5 
metal) is deposited onto a silicon wafer substrate and 
patterned into dots having the diameter of the desired 
microneedles. The wafer is then subjected to a carefully 
controlled plasma based on fluorine/oxygen chemistries to 
etch very deep, high aspect ratio trenches into the silicon. 10 
See, e.g., Jansen, et al., "The Black Silicon Method IV: The 
Fabrication of Three-Dimensional Structures in Silicon with 
High Aspect Ratios for Scanning Probe Microscopy and 
Other Applications," IEEE Proceedings of Micro Electro 
Mechanical Systems Conference, pp. 88-93 (1995). Those 15 
regions protected by the metal mask remain and form the 
needles. This method is further described in Example 1 
below. FIG. 4 provides a diagram of micro needles fabricated 
by this method. 
8 
pores greater than 50 nm. The mesoporous regime is 
expected to be most useful for drug delivery. Two 
approaches to porous needles are generally available, either 
(a) the silicon wafer is first made porous and then etched as 
described above to form needles or (b) solid micro needles 
are etched and then rendered porous by means of electro-
chemical oxidation, such as by anodization of a silicon 
substrate in a hydrofluoric acid electrolyte. The size distri-
bution of the etched porous structure is highly dependent on 
several variables, including doping kind and illumination 
conditions, as detailed in Lehmann, "Porous Silicon-A 
New Material for MEMS", IEEE Proceedings of the Micro 
Electro Mechanical Systems Conference, pp. 1-6 (1996). 
ii. Hollow Needles 
In this approach, one or more distinct and continuous 
pathways are created through the interior of micro needles. In 
a preferred embodiment, the microneedle has a single annu-
lar pathway along the center axis of the microneedle. This 
can be achieved by initially chemically or physically etching 
iii. Electroplating 20 the holes in the material and then etching away microneedles 
around the hole. Alternatively, the microneedles and their 
holes can be made simultaneously or holes can be etched 
into existing microneedles. As another option, a microneedle 
In this process, a metal layer is first evaporated onto a 
planar substrate. A layer of photoresist is then deposited onto 
the metal to form a patterned mold which leaves an exposed-
metal region in the shape of needles. By electroplating onto 
the exposed regions of the metal seed layer, the mold 25 
bounded by photoresist can be filled with electroplated 
material. Finally, the substrate and photoresist mold are 
removed, leaving the finished microneedle array. The 
microneedles produced by this process generally have diam-
eters on the order of 1 µm or larger. See, e.g., Frazier, et al., 30 
"Two dimensional metallic microelectrode arrays for extra-
cellular stimulation and recording of neurons", IEEE Pro-
ceedings of the Micro Electro Mechanical Systems 
Conference, pp. 195-200 (1993). 
form can be made, then coated, and then etched away, 
leaving only the outer coating to form a hollow microneedle. 
Coatings can be formed either by deposition of a film or by 
oxidation of the silicon microneedles to a specific thickness, 
followed by removal of the interior silicon. Also, holes from 
the backside of the wafer to the underside of the hollow 
needles can be created using a front-to-backside infrared 
alignment followed by etching from the backside of the 
wafer. 
One method for hollow needle fabrication is to replace the 
solid mask used in the formation of solid needles by a mask 
iv. Other Processes 
Another method for forming microneedles made of sili-
con or other materials is to use microfabrication techniques 
35 that includes a solid shape with one or more interior regions 
of the solid shape removed. One example is a "donut-
shaped" mask. Using this type of mask, interior regions of 
the needle are etched simultaneously with their side walls. to make a mold form (A), transferring that mold form to 
other materials using standard mold transfer techniques, 
such as embossing or injection molding (B), and reproduc- 40 
ing the shape of the original mold form (A) using the 
newly-created mold (B) to yield the final microneedles (C). 
Alternatively, the creation of the mold form (A) could be 
skipped and the mold (B) could be microfabricated directly, 
which could then be used to create the final microneedles 45 
(C). 
Another method of forming solid silicon microneedles is 
by using epitaxial growth on silicon substrates, as is utilized 
Due to lateral etching of the inner side walls of the needle, 
this may not produce sufficiently sharp walls. In that case, 
two plasma etches must be used, one to form the outer walls 
of the microneedle (i.e., the 'standard' etch), and one to form 
the inner hollow core (which is an extremely anisotropic 
etch, such as in inductively-coupled-plasma (ICP) etch). 
This structure can be achieved by substituting the chromium 
mask for the solid microneedles by a silicon nitride layer 
covered with chromium. Solid microneedles are then etched, 
the chromium is stripped, and the silicon is oxidized. The 
silicon nitride layer will prevent oxidation at the needle tip. by Containerless Research, Inc. (Evanston, Ill., USA) for its 
products. 
b. Hollow or Porous Microneedles 
In a preferred embodiment, microneedles are made with 
pores or other pathways through which material may be 
transported. The following descriptions outline representa-
tive methods for fabricating either hollow or porous micron-
eedles. 
50 The silicon nitride is then stripped, leaving exposed silicon 
at the tip of the needle and oxide-covered silicon everywhere 
else. The needle is then exposed to an ICP plasma which 
selectively etches the silicon in a highly anisotropic manner 
to form the interior hole of the needle. FIGS. Sa and Sb 
55 illustrate examples of a donut-shaped mask and a micron-
eedle formed thereby, respectively. 
i. Porous Microneedles 
Rather than having a single, well-defined hole down the 
length of the needle, porous needles are filled with a network 
of channels or pores which allow conduction of fluid or 60 
energy through the needle shaft. It has been shown that by 
appropriate electrochemical oxidation of silicon, pore arrays 
with high aspect ratios and a range of different pore size 
regimes can be formed; these pore regimes are defined as (1) 
microporous regime with average pore dimensions less than 65 
2 nm, (2) mesoporous regime with average pore sizes of 
between 2 nm and 50 nm, and (3) macroporous regime with 
A second method uses the solid silicon needles described 
previously as 'forms' around which the actual needle struc-
tures are deposited. After deposition, the forms are etched 
away, yielding the hollow structures. Silica needles or metal 
needles can be formed using different methods. Silica 
needles can be formed by creating needle structures similar 
to the ICP needles described above prior to the oxidation 
described above. The wafers are then oxidized to a con-
trolled thickness, forming a layer on the shaft of the needle 
form which will eventually become the hollow microneedle. 
The silicon nitride is then stripped and the silicon core 
US 6,503,231 Bl 
9 
selectively etched away (e.g., in a wet alkaline solution) to 
form a hollow silica microneedle. 
Metal needles can be formed by physical vapor deposition 
of appropriate metal layers on solid needle forms, which can 
be made of silicon using the techniques described above, or 5 
which can be formed using other standard mold techniques 
such as embossing or injection molding. The metals are 
selectively removed from the tips of the needles using 
electropolishing techniques, in which an applied anodic 
potential in an electrolytic solution will cause dissolution of 10 
metals more rapidly at sharp points, due to concentration of 
electric field lines at the sharp points. Once the underlying 
silicon needle forms have been exposed at the tips, the 
silicon is selectively etched away to form hollow metallic 
needle structures. This process could also be used to make 15 
hollow needles made from other materials by depositing a 
material other than metal on the needle forms and following 
the procedure described above. 
Hollow needles made from silicon dioxide similarly may 
be made by oxidizing the surface of the silicon needle forms, 20 
rather than depositing a metal, and then etching away the 
solid needle forms and leaving the hollow silicon dioxide 
structures, as illustrated in FIGS. 6a-6d. FIG. 6a shows an 
array of needle forms with masks on their tips. In FIG. 6b, 
the needle forms have been coated with a layer of metal, 25 
silicon dioxide or other material. FIG. 6c shows the coated 
needle forms with the masks removed. Finally, in FIG. 6d, 
the needle forms have been etched away, leaving hollow 
needles made of metal, silicon dioxide, or other materials. 
10 
housing containing drug in an internal reservoir, wherein the 
housing has a bioadhesive coating around the microneedles. 
The patient can remove a peelaway backing to expose an 
adhesive coating, and then press the device onto a clean part 
of the skin, leaving it to administer drug over the course of, 
for example, several days. 
a. Drug Delivery 
Essentially any drug or other bioactive agents can be 
delivered using these devices. Drugs can be proteins, 
enzymes, polysaccharides, polynucleotide molecules, and 
synthetic organic and inorganic compounds. A preferred 
drug is insulin. Representative agents include anti-
infectives, hormones, and growth regulators. The drug can 
be for local treatment or for regional or systemic therapy. 
In this way, many drugs can be delivered at a variety of 
therapeutic rates. The rate can be controlled by varying a 
number of design factors, including the outer diameter of the 
microneedle, the number and size of pores or channels in 
each microneedle, the number of microneedles in an array, 
the magnitude and frequency of application of the force 
driving the drug through the microneedle and/or the holes 
created by the microneedles. For example, devices designed 
to deliver drug at different rates might have more micron-
eedles for more rapid delivery and fewer microneedles for 
less rapid delivery. As another example, a device designed to 
deliver drug at a variable rate could vary the driving force 
(e.g., pressure gradient controlled by a pump) for transport 
according to a schedule which was pre-programmed or 
controlled by, for example, the user or his doctor. The 
In one embodiment, hollow, porous, or solid microneedles 
are provided with longitudinal grooves or other modifica-
tions to the exterior surface of the microneedles. Grooves, 
30 devices can be affixed to the skin or other tissue to deliver 
for example, should be useful in directing the flow of 
molecules along the outside of microneedles. 
drugs continuously or intermittently, for durations ranging 
from a few seconds to several hours or days. 
One of skill in the art can measure the rate of drug 
delivery for particular microneedle devices using in vitro 
4. Microneedle Device Applications 
The device may be used for a single or for multiple uses 
for rapid transport across a biological barrier or may be left 
35 and in vivo methods known in the art. For example, to 
measure the rate of transdermal drug delivery, human 
cadaver skin mounted on standard diffusion chambers can be 
used to predict actual rates. See Hadgraft & Guy, eds., in place for longer times (e.g., days or months) for long-term 
transport of molecules. Depending on the dimensions of the 
device, the application site, and the route in which the device 40 
is introduced into (or onto) the biological barrier, the device 
may be used to introduce or remove molecules at specific 
locations. 
As discussed above, FIG. 3 is a side elevational view of 
a schematic of a preferred embodiment of the microneedle 45 
device in a transdermal application. The device 10 is applied 
to the skin such that the microneedles 12 penetrate through 
the stratum corneum and enter the viable epidermis so that 
the tip of the microneedle at least penetrates into the viable 
epidermis. In a preferred embodiment, drug molecules in a 50 
reservoir within the upper portion 11 flow through or around 
the microneedles and into the viable epidermis, where the 
drug molecules then diffuse into the dermis for local treat-
ment or for transport through the body. 
To control the transport of material out of or into the 55 
device through the microneedles, a variety of forces or 
mechanisms can be employed. These include pressure 
gradients, concentration gradients, electricity, ultrasound, 
receptor binding, heat, chemicals, and chemical reactions. 
Mechanical or other gates in conjunction with the forces and 60 
mechanisms described above can be used to selectively 
control transport of the material. 
In particular embodiments, the device should be "user-
friendly. " For example, in some transdermal applications, 
affixing the device to the skin should be relatively simple, 65 
and not require special skills. This embodiment of a micron-
eedle may include an array of microneedles attached to a 
Transdermal Drug Delivery: Developmental Issues and 
Research Initiatives (Marcel Dekker, New York 1989); 
Bronaugh & Maibach, Percutaneous Absorption, 
Mechanisms-Methodology-Drug Delivery (Marcel 
Dekker, New York 1989). After filling the compartment on 
the dermis side of the diffusion chamber with saline, a 
microneedle array is inserted into the stratum corneum; a 
drug solution is placed in the reservoir of the microneedle 
device; and samples of the saline solution are taken over 
time and assayed to determine the rates of drug transport. 
b. Diagnostic Sensing of Body Fluids (Biosensors) 
One embodiment of the devices described herein may be 
used to remove material from the body across a biological 
barrier, i.e. for minimally invasive diagnostic sensing. For 
example, fluids can be transported from interstitial fluid in a 
tissue into a reservoir in the upper portion of the device. The 
fluid can then be assayed while in the reservoir or the fluid 
can be removed from the reservoir to be assayed, for 
diagnostic or other purposes. For example, interstitial fluids 
can be removed from the epidermis across the stratum 
corneum to assay for glucose concentration, which should 
be useful in aiding diabetics in determining their required 
insulin dose. Other substances or properties that would be 
desirable to detect include lactate (important for athletes), 
oxygen, pH, alcohol, tobacco metabolites, and illegal drugs 
(important for both medical diagnosis and law enforcement). 
In one embodiment, one or more microneedle devices can 
be used for (1) withdrawal of interstitial fluid, (2) assay of 
the fluid, and (3) delivery of the appropriate amount of a 
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therapeutic agent based on the results of the assay, either 
automatically or with human intervention. For example, a 
sensor delivery system may be combined to form, for 
example, a system which withdraws bodily fluid, measures 
its glucose content, and delivers an appropriate amount of 5 
insulin. 
Products, Rochester, N.Y.). The chromium layer was pat-
terned into 20 by 20 arrays of 80 µm diameter dots with 150 
µm center-to-center spacing using the lithographic process 
described below. 
A layer of photosensitive material (1827 photoreist, 
Shipley, Marlborough, Mass.) was deposited onto the chro-
mium layer covering the silicon wafers. A standard litho-
graphic mask (Telic, Santa Monica, Calif.) bearing the 
appropriate dot array pattern was positioned on top of the 
c. Other Applications 
The microneedle devices disclosed herein should be use-
ful for penetrating individual cells, for example in gene 
transfer. See e.g., Hashmi, et al., "Genetic transformation of 
menatodes using arrays of micromechanical piercing 
structures," BioTechniques 19:766-770 (1995); Trimmer et 
al., "Injection of DNA into Plant and Animal Tissues with 
Micro mechanical Piercing Structures", IEEE Proceedings of 
the Micro Electro Mechanical Systems Conference, pp. 
111-15 (1995). 
Other than transport of drugs and biological molecules, 
the microneedles may be used to transmit or transfer other 
materials and energy forms, such as light, electricity, heat, or 
pressure. The microneedles, for example, could be used to 
direct light to specific locations within the body, in order that 
the light can directly act on a tissue or on an intermediary, 
such as light-sensitive molecules in photodynamic therapy. 
The microneedle devices disclosed herein also should be 
useful for controlling transport across tissues other than 
skin. For example, microneedles could be inserted into the 
eye across, for example, conjunctiva, sclera, and/or cornea, 
to facilitate delivery of drugs into the eye. Similarly, micron-
eedles inserted into the eye could facilitate transport of fluid 
out of the eye, which may be of benefit for treatment of 
glaucoma. Microneedles may also be inserted into the buc-
cal (oral), nasal, vaginal, or other accessible mucosa to 
facilitate transport into, out of, or across those tissues. For 
example, a drug may be delivered across the buccal mucosa 
for local treatment in the mouth or for systemic uptake and 
delivery. As another example, microneedle devices may be 
used internally within the body on, for example the lining of 
the gastrointestinal tract to facilitate uptake of orally-
ingested drugs or the lining of blood vessels to facilitate 
penetration of drugs into the vessel wall. These uses may 
involve invasive procedures to introduce the microneedle 
devices into the body or could involve swallowing, inhaling, 
injecting or otherwise introducing the devices m a non-
invasive or minimally-invasive manner. 
EXAMPLE 1 
Fabrication of Microneedles 
10 photoresist layer. The wafer and photoreist were then 
exposed to ultraviolet (UV) light through the mask by means 
of an optical mask aligner (Hybralign Series 500, Optical 
Associates, Inc., Milpitas, Calif.). The exposed photoresist 
was removed by soaking the wafers in a liquid developer 
15 (354 developer, Shipley, Marlborough, Mass.) leaving the 
desired dot array of photoresist on the chromium layer. 
Subsequently, the wafers were dipped into a chromium 
etchant (CR-75; Cyanteck Fremont, Calif.), which etched 
the chromium that had been exposed during the photolithog-
20 raphy step, leaving dot arrays of chromium (covered with 
photoresist) on the surface of the silicon wafer. The photo-
resist still present on the chromium dots formed the masks 
needed for fabrication of the micro needles, described below. 
The microneedles were fabricated using a reactive ion 
25 etching techniques based on the Black Silicon Method 
developed at the University ofTwente. The patterned wafers 
were etched in a reactive ion etcher (700 series wafer/batch 
Plasma Processing System, Plasma Therm, St. Petersburg, 
Fla.) with means for ensuring good thermal contact between 
30 the wafers and the underlying platen (Apiezon N, K. J. 
Lesker, Clairton, Pa.). The wafers were etched using the 
following gases and conditions: SF 6 (20 standard cubic 
centimeters per minute) and 0 2 (15 standard cubic centime-
ters per minute) at a pressure of 150 mTorr and a power of 
35 150 W for a run time of approximately 250 minutes. These 
conditions caused both deep vertical etching and slight 
lateral underetching. By controlling the ratio of flow rates of 
the SF 6 and 0 2 gases used to form the plasma, the aspect 
ratio of the microneedles could be adjusted. The regions 
40 protected by the chromium masks remained and formed the 
microneedles. Etching was allowed to proceed until the 
masks fell off due to underetching, resulting in an array of 
sharp silicon spikes. 
45 EXAMPLE 2 
Transdermal Transport Using Microneedles 
A chromium masking material was deposited onto silicon 
wafers and patterned into dots having a diameter approxi- 50 
mately equal to the base of the desired microneedles. The 
wafers were then loaded into a reactive ion etcher and 
subjected to a carefully controlled plasma based on fluorine/ 
oxygen chemistries to etch very deep, high aspect ratio 
valleys into the silicon. Those regions protected by the metal 55 
mask remain and form the microneedles. 
To determine if microfabricated microneedles could be 
used to enhance transdermal drug delivery, arrays of micron-
eedles were made using a deep plasma etching technique. 
Their ability to penetrate human skin without breaking was 
tested and the resulting changes in transdermal transport 
were measured. 
Arrays of microneedles were fabricated having extremely 
sharp tips (radius of curvature less than 1 µm) which 
facilitate easy piercing into the skin, and are approximately 
150 µm long. Because the skin surface is not fiat due to 
dermatoglyphics (i.e. tiny wrinkles) and hair, the full length 
of these micro needles will not penetrate the skin. All experi-
ments were performed at room temperature (23±2° C.). 
<100>-oriented, prime grade, 450--550 µm thick, 10-15 
Q-cm silicon wafers (Nova Electronic Materials Inc., 
Richardson, Tex.) were used as the starting material. The 
wafers were cleaned in a solution of 5 parts by volume 60 
deionized water, 1 part 30% hydrogen peroxide, and 1 part 
30% ammonium hydroxide (J. T. Baker, Phillipsburg, N.J.) 
at approximately 80° C. for 15 minutes, and then dried in an 
oven (Blue M Electric, Watertown, Wis.) at 150° C. for 10 
minutes. Approximately 1000 A of chromium (Mat-Vac 65 
Technology, Flagler Beach, Fla.) was deposited onto the 
wafers using a DC-sputterer (601 Sputtering System, CVC 
The ability of the microneedles to pierce skin without 
breaking was then tested. Insertion of the arrays into skin 
required only gentle pushing. Inspection by light and elec-
tron microscopy showed that more than 95% of micron-
eedles within an array pierced across the stratum corneum of 
the epidermis samples. Moreover, essentially all of the 
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microneedles that penetrated the epidermis remained intact. 
On those very few which broke, only the top 5-10 µm was 
damaged. Microneedle arrays could also be removed with-
out difficulty or additional damage, as well as re-inserted 
into skin multiple times. 5 
To quantitatively assess the ability of microneedles to 
increase transdermal transport, calcein permeability of 
human epidermis with and without inserted microneedle 
arrays was measured. Calcein crosses skin very poorly under 
normal circumstances and therefore represents an especially 10 
difficult compound to deliver. As expected, passive perme-
ability of calcein across unaltered skin was very low, indi-
cating that the epidermis samples were intact. 
Insertion of microneedles into skin was capable of dra-
matically increasing permeability to calcein. When micron- 15 
eedles were inserted and left embedded in the skin, calcein 
permeability was increased by more than 1000-fold. Inser-
tion of microneedles for 10 s, followed by their removal, 
yielded an almost 10,000-fold increase. Finally, insertion of 
14 
Those skilled in the art will recognize, or be able to 
ascertain using on, many equivalents to the specific embodi-
ments of the invention described herein. Such equivalents 
are following claims. 
We claim: 
1. A device for transport of material or energy across 
biological barriers comprising: 
a plurality of hollow microneedles having a length 
between 100 µm and 1 mm, and 
a substrate to which the microneedles are attached or 
integrally formed, the microneedles extending at an 
angle from the substrate, 
wherein the microneedles are made by a microfabrica-
tion technique from a material selected from the 
group consisting of silicon, silicon dioxide, metals, 
ceramics, and combinations thereof, and 
wherein each microneedle has a shaft, a portion of 
which comprises one or more substantially annular 
bores or channels therethrough and which has a 
width between about 1 µm and 100 µm. 
2. The device of claim 1 wherein the microfabrication 
technique is a micromachining technique selected from the 
group consisting of lithography, plasma etching, wet chemi-
cal etching, dry etching, thermal oxidation of silicon, 
electroplating, electroless plating, boron diffusion, phospho-
a microneedle array for 1 h, followed by its removal, 20 
increased skin permeability by about 25,000-fold. Perme-
abilities for skin with microneedles inserted and then 
removed are higher than for skin with microneedles remain-
ing embedded probably because the microneedles them-
selves or the silicon plate supporting the array may block 
access to the microscopic holes created in the skin. Light 
microscopy showed that the holes which remained in the 
skin after microneedles were removed were approximately 1 
25 rus diffusion, arsenic diffusion, antimony diffusion, ion 
implantation, film deposition, sputtering, chemical vapor 
deposition, epitaxy, chemical anodization, electrochemical 
anodization, and combinations thereof. 
µmin size. 
To confirm in vitro experiments which showed that skin 
permeability can be significantly increased by microneedles, 
studies were conducted with human volunteers. They indi-
cated that microneedles could be easily inserted into the skin 
30 
of the forearm or hand. Moreover, insertion of microneedle 
35 
arrays was never reported to be painful, but sometimes 
elicited a mild "wearing" sensation described as a weak 
pressure or the feeling of a piece of tape affixed to the skin. 
Although transport experiments were not performed in vivo, 
skin electrical resistance was measured before and after 
40 
microneedle insertion. Microneedles caused a 50-fold drop 
in skin resistance, a drop similar to that caused by the 
insertion of a 30-gauge "macro needle". Inspection of the site 
immediately after microneedle insertion showed no holes 
visible by light microscopy. No erythema, edema or other 
45 
reaction to microneedles was observed over the hours and 
days which followed. This indicates that microneedle arrays 
can permeabilize skin in human subjects in a non-painful 
and safe manner. 
Publications cited herein and the material for which they 
are cited are specifically incorporated by reference. 
3. The device of claim 1 wherein the width of the entire 
shaft of the microneedles is between about 1 µm and 100 µm. 
4. The device of claim 1 wherein the length of the 
microneedles are between about 100 µm and 500 µm. 
5. The device of claim 1 wherein the microneedles are in 
communication with a reservoir. 
6. The device of claim 1 wherein the material comprises 
a metal. 
7. The device of claim 1 wherein one or more of the 
microneedles each comprise a base end which tapers to a 
sharp tip end, wherein the width of the base end is between 
about 10 µm and 100 µm. 
8. The device of claim 1 wherein the angle is about 90°. 
9. The device of claim 6 wherein the material consists 
essentially of metal. 
10. The device of claim 1, wherein the substrate com-
prises a metal. 
11. The device of claim 5, wherein the reservoir contains 
a drug. 
12. The device of claim 11, wherein the drug comprises 
insulin. 
* * * * * 
